Scientific Program
Bronchial Asthma I
Session Chairs: Mohamed Al-Hajjaj (UAE) | Mohamed Zeitouni (KSA)
09:00
SINA Perspective in Managing Stable Asthma in 2022
Mohamed Al-Moamary (KSA)
09:20
Allergic Rhinitis and Asthma: The Knowns and Unknowns
Rand Arnaout (KSA)
09:40
Effect of Climate Change and Global Warming on Asthma
Ignacio Ansotegui (Spain)
11:00
Panel Discussion Q&A
11:15 – 13:30
Break / Lunch
COPD II
Session Chairs: Hamdan Al-Jahdali (KSA) | Shareefah Basheri (KSA)
13:30
Clinical, Inflammatory, Endo-Phenotyping of COPD:
Implications, Pitfalls and Future Directions
Antonio Anzueto (USA)
13:50
Endoscopic Lung Volume Reduction: Facts, Figures and Future Directions
Grigoris Stratakos (Greece)
14:10
Defining and Halting the Progression of Early COPD
Antonio Anzueto (USA)
14:50
Panel Discussion Q&A
15:00 – 15:30
Coffee Break
Sarcoidosis
Session Chairs: Esam Alhamad (KSA) | Rahmah Alsilmi (KSA)
15:30
Sarcoidosis with Pulmonary Fibrosis: In Whom, When, and How?
Paolo Spagnolo (Italy)
15:50
Clinical Phenotypes in Sarcoidosis
Elena Bargagli (Italy)
16:10
Pro-Con debate: Fibrotic Pulmonary Sarcoidosis Should Receive Antifibrotic
Pro
Vasilis Kouranos (UK)
Con
Argyris Tzouvelekis (Greece)
16:40
Pro-Con Debate: SAPH Should Receive PH Specific Therapy
Pro
Steven Nathan (USA)
Con
Luke Howard (UK)
17:30
Panel Discussion Q&A
17:40 – 18:10
Coffee Break
Pulmonary Hypertension
Session Chairs: Majdy Idrees (KSA) | Badr Al-Ghamdi (KSA)
18:10
Switching Treatment Within the Same Class; is it Evidence-Based?
Nasser Al Busaidi (Oman)
18:30
Debate: RV or PVR, Which Should be the Main Target?
RV should be the main target
Tarek Kashour (KSA)
PVR Should be the main target
Luke Howard (UK)
19:00
Reversing RV Remodelling in PH; is it Possible?
Hussam Sakkijha (KSA)
19:20
Panel Discussion Q&A